These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7811014)

  • 1. Sterol composition of Cryptococcus neoformans in the presence and absence of fluconazole.
    Ghannoum MA; Spellberg BJ; Ibrahim AS; Ritchie JA; Currie B; Spitzer ED; Edwards JE; Casadevall A
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2029-33. PubMed ID: 7811014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei.
    Sanati H; Belanger P; Fratti R; Ghannoum M
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2492-6. PubMed ID: 9371355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.
    Venkateswarlu K; Taylor M; Manning NJ; Rinaldi MG; Kelly SL
    Antimicrob Agents Chemother; 1997 Apr; 41(4):748-51. PubMed ID: 9087482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sterol compositions and susceptibilities to amphotericin B of environmental Cryptococcus neoformans isolates are changed by murine passage.
    Currie B; Sanati H; Ibrahim AS; Edwards JE; Casadevall A; Ghannoum MA
    Antimicrob Agents Chemother; 1995 Sep; 39(9):1934-7. PubMed ID: 8540694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients.
    Lamb DC; Corran A; Baldwin BC; Kwon-Chung J; Kelly SL
    FEBS Lett; 1995 Jul; 368(2):326-30. PubMed ID: 7628631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of amphotericin B on the lipids of five different strains of Cryptococcus neoformans.
    Franzot SP; Hamdan JS
    Mycopathologia; 1994 Nov; 128(2):85-9. PubMed ID: 7777038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of three azole derivatives on the lipids of different strains of Cryptococcus neoformans.
    Franzot SP; Hamdan JS
    Mycoses; 1995; 38(5-6):183-9. PubMed ID: 8531929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro susceptibility of Cryptococcus neoformans isolates to fluconazole and itraconazole.
    Davey KG; Johnson EM; Holmes AD; Szekely A; Warnock DW
    J Antimicrob Chemother; 1998 Aug; 42(2):217-20. PubMed ID: 9738839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid substitution in Cryptococcus neoformans lanosterol 14-α-demethylase involved in fluconazole resistance in clinical isolates.
    Bosco-Borgeat ME; Mazza M; Taverna CG; Córdoba S; Murisengo OA; Vivot W; Davel G
    Rev Argent Microbiol; 2016; 48(2):137-42. PubMed ID: 27311753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole.
    Casadevall A; Spitzer ED; Webb D; Rinaldi MG
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1383-6. PubMed ID: 8328793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans.
    Vanden Bossche H; Marichal P; Le Jeune L; Coene MC; Gorrens J; Cools W
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2101-5. PubMed ID: 8257130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
    Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitrogen concentration affects amphotericin B and fluconazole tolerance of pathogenic cryptococci.
    Bosch C; Toplis B; Vreulink JM; Volschenk H; Botha A
    FEMS Yeast Res; 2020 Mar; 20(2):. PubMed ID: 32073632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.
    Nielsen K; Vedula P; Smith KD; Meya DB; Garvey EP; Hoekstra WJ; Schotzinger RJ; Boulware DR
    Med Mycol; 2017 Jun; 55(4):453-456. PubMed ID: 27664991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreasing fluconazole susceptibility of clinical South African Cryptococcus neoformans isolates over a decade.
    Naicker SD; Mpembe RS; Maphanga TG; Zulu TG; Desanto D; Wadula J; Mvelase N; Maluleka C; Reddy K; Dawood H; Maloba M; Govender NP;
    PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008137. PubMed ID: 32231354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of fluconazole on the sterol and carbohydrate composition of four species of Candida.
    Pfaller M; Riley J
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):152-6. PubMed ID: 1396728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W; Sungkanuparph S; Thongyen S; Chumpathat N; Eampokalap B; Thawornwan U; Foongladda S
    J Med Assoc Thai; 2006 Jun; 89(6):795-802. PubMed ID: 16850679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.
    Yamazumi T; Pfaller MA; Messer SA; Houston AK; Boyken L; Hollis RJ; Furuta I; Jones RN
    J Clin Microbiol; 2003 Jan; 41(1):267-72. PubMed ID: 12517859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates.
    Arthington-Skaggs BA; Lee-Yang W; Ciblak MA; Frade JP; Brandt ME; Hajjeh RA; Harrison LH; Sofair AN; Warnock DW;
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2477-81. PubMed ID: 12121921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients.
    Hoban DJ; Zhanel GG; Karlowsky JA
    Antimicrob Agents Chemother; 1999 Jun; 43(6):1463-4. PubMed ID: 10348771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.